MX2017012399A - Anticuerpos monoclonales anti-cd303. - Google Patents

Anticuerpos monoclonales anti-cd303.

Info

Publication number
MX2017012399A
MX2017012399A MX2017012399A MX2017012399A MX2017012399A MX 2017012399 A MX2017012399 A MX 2017012399A MX 2017012399 A MX2017012399 A MX 2017012399A MX 2017012399 A MX2017012399 A MX 2017012399A MX 2017012399 A MX2017012399 A MX 2017012399A
Authority
MX
Mexico
Prior art keywords
antibodies
plasmacytoid dendritic
monoclonal antibodies
bpdcn
chimeric
Prior art date
Application number
MX2017012399A
Other languages
English (en)
Inventor
Fontayne Alexandre
Fournier Nathalie
De Romeuf Christophe
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54937151&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017012399(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Publication of MX2017012399A publication Critical patent/MX2017012399A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención se relaciona a anticuerpos anti-CD303 quiméricos o humanizados para ácidos nucleicos que codifican para las cadenas pesadas y ligeras de estos anticuerpos, vectores de expresión, células hospedero, animales no humanos transgénicos o plantas transgénicas que expresan los anticuerpos, así como también a los usos de los mismos en el tratamiento o prevención de neoplasma de células dendríticas plasmacitoides blásticas (BPDCN) o enfermedades inflamatorias, en particular enfermedades autoinmunológicas, que implican células dendríticas plasmacitoides.
MX2017012399A 2015-03-31 2016-03-31 Anticuerpos monoclonales anti-cd303. MX2017012399A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1552757A FR3034420A1 (fr) 2015-03-31 2015-03-31 Anticorps monoclonaux anti-cd303
PCT/EP2016/056995 WO2016156450A1 (fr) 2015-03-31 2016-03-31 Anticorps monoclonaux anti-cd303

Publications (1)

Publication Number Publication Date
MX2017012399A true MX2017012399A (es) 2018-01-26

Family

ID=54937151

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017012399A MX2017012399A (es) 2015-03-31 2016-03-31 Anticuerpos monoclonales anti-cd303.
MX2021014818A MX2021014818A (es) 2015-03-31 2017-09-27 Anticuerpos monoclonales anti-cd303.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021014818A MX2021014818A (es) 2015-03-31 2017-09-27 Anticuerpos monoclonales anti-cd303.

Country Status (13)

Country Link
US (3) US10611843B2 (es)
EP (2) EP3277720A1 (es)
JP (2) JP6829210B2 (es)
KR (1) KR20170132819A (es)
CN (1) CN107660212A (es)
AR (1) AR104156A1 (es)
AU (1) AU2016239936A1 (es)
BR (1) BR112017020698A2 (es)
CA (1) CA2981093A1 (es)
ES (1) ES2819902T3 (es)
FR (2) FR3034420A1 (es)
MX (2) MX2017012399A (es)
WO (2) WO2016156449A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2968561B1 (fr) * 2010-12-13 2013-08-09 Lfb Biotechnologies Utilisation d'un anticorps dirige contre une proteine membranaire
FR3034420A1 (fr) 2015-03-31 2016-10-07 Lab Francais Du Fractionnement Anticorps monoclonaux anti-cd303
FR3045386B1 (fr) 2015-12-16 2018-02-02 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation d'un anticorps dirige contre une proteine membranaire
FR3060395B1 (fr) * 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combinaison d'anticorps anti-cd303 et anti-her2
FR3060394B1 (fr) * 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combinaison d'anticorps anti-cd303 et anti-amhrii
US11701387B2 (en) * 2018-01-04 2023-07-18 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor specific for BDCA2 antigen
WO2020252381A2 (en) * 2019-06-13 2020-12-17 Allogene Therapeutics, Inc. Anti-talen antibodies and uses thereof
CN114516915B (zh) * 2020-11-19 2023-03-28 东莞市朋志生物科技有限公司 抗n末端脑钠肽前体的抗体以及制备抗体的方法
CN116199772B (zh) * 2022-11-16 2023-10-17 怡道生物科技(苏州)有限公司 Hpv31型衣壳蛋白l1单克隆抗体、制备方法及应用
CN116693687B (zh) * 2023-08-03 2023-10-03 天津旷博同生生物技术有限公司 一种抗人cd25工程抗体及应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
CA2350233A1 (en) 1998-11-02 2000-05-11 Genzyme Transgenics Corp. Transgenic and cloned mammals
PL220113B1 (pl) 1999-01-15 2015-08-31 Genentech Inc Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
EP2270150B2 (en) 1999-04-09 2019-08-07 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP1220606A4 (en) 1999-10-14 2004-04-14 Gtc Biotherapeutics Inc METHODS OF PRODUCING A TARGET MOLECULE IN A TRANSGENIC ANIMAL AND OF PURIFYING THE TARGET MOLECULE
AU785198B2 (en) * 1999-11-15 2006-11-02 Miltenyi Biotec B.V. & Co. KG Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognised thereby and cells obtained thereby
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
ES2727425T3 (es) 2000-12-12 2019-10-16 Medimmune Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
CA2506629A1 (en) 2002-11-27 2004-06-17 Gtc Biotherapeutics, Inc. Modified antibodies stably produced in milk and methods of producing same
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
MXPA06003553A (es) 2003-09-30 2007-02-02 Sterrenbeld Biotechnologie North America Inc Un proceso para producir proteina exogena en la leche de mamiferos transgenicos y un proceso para purificar proteinas de la leche.
JP5011520B2 (ja) 2005-08-12 2012-08-29 国立大学法人 長崎大学 新規ヒト形質細胞様樹状細胞株
CN103435695A (zh) 2005-10-21 2013-12-11 Gtc生物治疗有限公司 具有增强的抗体依赖性细胞毒性活性的抗体及其生产方法和用途
US7531632B2 (en) 2006-02-16 2009-05-12 Gtc Biotherapeutics, Inc. Clarification of transgenic milk using depth filtration
WO2008028686A2 (en) 2006-09-10 2008-03-13 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
CN110317272A (zh) 2008-10-14 2019-10-11 霍夫曼-拉罗奇有限公司 免疫球蛋白变体及其用途
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
FR2957598B1 (fr) 2010-03-17 2015-12-04 Lfb Biotechnologies Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
FR2968561B1 (fr) 2010-12-13 2013-08-09 Lfb Biotechnologies Utilisation d'un anticorps dirige contre une proteine membranaire
EP2537864B1 (en) 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
FR2981946B1 (fr) 2011-10-28 2015-02-20 Lfb Biotechnologies Unites de transcription et leur utilisation dans des vecteurs d'expression (yb2/0)
FR2986536A1 (fr) 2012-02-08 2013-08-09 Lfb Biotechnologies Unites de transcription et leur utilisation dans des vecteurs d'expression (cho)
US9175691B2 (en) * 2012-10-03 2015-11-03 Praxair Technology, Inc. Gas compressor control system preventing vibration damage
JP6490591B2 (ja) * 2012-12-10 2019-03-27 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 抗血液樹状細胞抗原２抗体およびその使用
CN109535254B (zh) 2013-12-24 2022-06-24 安斯泰来制药株式会社 抗人bdca-2抗体、其生产方法、多核苷酸、表达载体、宿主细胞及医药组合物
FR3034420A1 (fr) 2015-03-31 2016-10-07 Lab Francais Du Fractionnement Anticorps monoclonaux anti-cd303

Also Published As

Publication number Publication date
JP2018511328A (ja) 2018-04-26
KR20170132819A (ko) 2017-12-04
AU2016239936A1 (en) 2017-10-12
WO2016156450A1 (fr) 2016-10-06
CN107660212A (zh) 2018-02-02
CA2981093A1 (fr) 2016-10-06
MX2021014818A (es) 2022-01-18
US20200277385A1 (en) 2020-09-03
FR3034420A1 (fr) 2016-10-07
AR104156A1 (es) 2017-06-28
BR112017020698A2 (pt) 2018-06-26
FR3034430A1 (fr) 2016-10-07
US20180086834A1 (en) 2018-03-29
FR3034430B1 (fr) 2024-03-29
JP6829210B2 (ja) 2021-02-10
US10239946B2 (en) 2019-03-26
US10611843B2 (en) 2020-04-07
WO2016156449A1 (fr) 2016-10-06
ES2819902T3 (es) 2021-04-19
JP2018512144A (ja) 2018-05-17
EP3277723B1 (fr) 2020-06-17
US20180066060A1 (en) 2018-03-08
EP3277723A1 (fr) 2018-02-07
EP3277720A1 (fr) 2018-02-07

Similar Documents

Publication Publication Date Title
MX2021014818A (es) Anticuerpos monoclonales anti-cd303.
MX2017006802A (es) Animales no humanos que expresan el complejo cd3 humanizado.
MX2016016903A (es) Animales no humanos que tienen un gen de muerte celular programada 1 humanizado.
PH12016500342A1 (en) Non-human animals having a humanized signal-regulatory protein gene
MX2017007293A (es) Animales no humanos que tienen un gen del grupo de diferenciacion 47 humanizado.
MY178882A (en) Non-human animals with modified immunoglobulin heavy chain sequences
MX2016009050A (es) Construcciones biespecificas de union a los antigenos cd3 y cd19.
MX2021000484A (es) Animales no humanos que expresan secuencias de inmunoglobulina sensibles al ph.
MX2017007636A (es) Animales no humanos que tienen un gen del grupo de diferenciacion 274 humanizado.
SG194466A1 (en) Non-human animals expressing antibodies having a common light chain
MX2014012977A (es) Anticuerpos anti-cd22.
RU2014108208A (ru) Мыши с гуманизированной универсальной легкой цепью
CY1123046T1 (el) Ζωα εκτος του ανθρωπου που εχουν ανθρωποποιημενους υποδοχεις fc-γ
NZ627977A (en) Humanized rodents that express heavy chains containing vl domains
EP4249507A3 (en) Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
PH12017501090A1 (en) Parental rnai suppression of kruppel gene to control coleopteran pests
MX2017007533A (es) Supresion por iarn parental de los genes de remodelacion de cromatina para controlar las plagas de hemipteros.
ZA202001389B (en) Non-human animals expressing humanized c1q complex
MX2017007536A (es) Supresion por iarn parental del gen kruppel para el control de las plagas de hemipteros.
TH1601001594A (th) สัตว์ที่ไม่ใช่มนุษย์ซึ่งมียีนโปรตีนควบคุมสัญญาณที่ได้รับการฮิวมาไนซ์
EA202090128A3 (ru) Антитела против антигена 2 дендритных клеток крови и их применение